An Eight-Year Experience of HDR Brachytherapy Boost for Localized Prostate Cancer: Biopsy and PSA Outcome

Bachand, François; Martin, André-Guy; Beaulieu, Luc; Harel, François; Vigneault, Éric

doi:10.1016/j.ijrobp.2008.05.003

Cited by 74 publications

(35 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One measure of this endpoint is posttreatment positive biopsy rates. Studies using HDR brachytherapy have reported posttreatment positive prostate biopsy rates of approximately 5e10% (21,22). Positive biopsy rates after radiation therapy, however, are not an accepted gold standard of treatment efficacy in part because of the relatively long time it takes for irradiated prostate cancer to achieve a pathophysiologic response and the risk of false positives.…”

Section: Discussionmentioning

confidence: 99%

Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment

et al. 2013

View full text Add to dashboard Cite

PURPOSE: To determine the utility of focal high-dose-rate brachytherapy for localized prostate cancer, we investigated the impact on target coverage and dose to organs at risk (OARs) with hemigland (HG) compared with whole-gland (WG) treatment. METHODS AND MATERIALS:A total of 10 WG implants were used to generate 10 WG and 20 HG (left and right) treatment plans optimized with the inverse planning simulation annealing algorithm using Oncentra MasterPlan (Nucletron B.V., Veenendaal, The Netherlands). The standard distribution of 17e18 catheters designed for WG was used to generate HG plans. The same OARs namely bladder, rectum, and urethra contours and dose constraints were applied for HG and WG plans. The HG contour was a modification of the WG contour whereby the urethra divided the prostate into HGs.

show abstract

Section: Discussionmentioning

confidence: 99%

Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment

et al. 2013

View full text Add to dashboard Cite

show abstract

“…For intermediate and high‐risk patients (PSA > 10 and/or Gleason score > 6 and/or stage > T2c), HDR brachytherapy is more commonly used, mainly as a boost strategy, producing excellent PSA control and negative biopsy results in patients with intermediate‐ and high‐risk prostate cancer 26, 27, 28. However, TIPPB alone is a treatment option for some low‐tier intermediate risk prostate cancer patients and can also be used as a boost modality 23, 24, 25…”

Section: System Descriptionmentioning

confidence: 99%

COMP report: CPQR technical quality control guidelines for low‐dose‐rate permanent seed brachytherapy

Beaulieu¹,

Radford

Villarreal-Barajas

2018

J Applied Clin Med Phys

Self Cite

View full text Add to dashboard Cite

The Canadian Organization of Medical Physicists (COMP), in close partnership with the Canadian Partnership for Quality Radiotherapy (CPQR) has developed a series of Technical Quality Control (TQC) guidelines for radiation treatment equipment. These guidelines outline the performance objectives that equipment should meet in order to ensure an acceptable level of radiation treatment quality. The TQC guidelines have been rigorously reviewed and field tested in a variety of Canadian radiation treatment facilities. The development process enables rapid review and update to keep the guidelines current with changes in technology. This article contains detailed performance objectives and safety criteria for low‐dose‐rate (LDR) permanent seed brachytherapy.

show abstract

“…Favourable short-term toxicity and disease control 13 make this procedure a preferred one in several Canadian centres. 16,19,20 Canadian centres offering prostate brachytherapy…”

Section: The Proceduresmentioning

confidence: 99%

“…With a median follow-up of 7 years, the 5-year disease-free survival for men with intermediate-risk disease treated with HDR and EBRT in a Canadian multicentre study was 98%. 18 The reported 5-year PRFS is 91%, 95% and 96% in single institution series from McGill University, 17 Sunnybrook Odette Cancer Centre, 18 and Centre hospitalier universitaire de Québec (CHUQ), 20 respectively (Table 1).…”

Section: Hdr Brachytherapy In Canadamentioning

confidence: 99%

Canadian Prostate Brachytherapy in 2012

Keyes

Crook

Morris

et al. 2013

CUAJ

View full text Add to dashboard Cite

Prostate brachytherapy can be used as a monotherapy for low-and intermediate-risk patients or in combination with external beam radiation therapy (EBRT) as a form of dose escalation for selected intermediate-and high-risk patients. Prostate brachytherapy with either permanent implants (low dose rate [LDR]) or temporary implants (high dose rate [HDR]) is emerging as the most effective radiation treatment for prostate cancer. Several large Canadian brachytherapy programs were established in the mid-to late-1990s. Prostate brachytherapy is offered in British Columbia, Alberta, Manitoba, Ontario, Quebec and New Brunswick. We anticipate the need for brachytherapy services in Canada will significantly increase in the near future. In this review, we summarize brachytherapy programs across Canada, contemporary eligibility criteria for the procedure, toxicity and prostate-specific antigen recurrence free survival (PRFS), as published from Canadian institutions for both LDR and HDR brachytherapy.

show abstract

An Eight-Year Experience of HDR Brachytherapy Boost for Localized Prostate Cancer: Biopsy and PSA Outcome

Cited by 74 publications

References 31 publications

Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment

Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment

COMP report: CPQR technical quality control guidelines for low‐dose‐rate permanent seed brachytherapy

Canadian Prostate Brachytherapy in 2012

Contact Info

Product

Resources

About